Analyst Price Target is $37.50
▲ +404.03% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Conversion Labs in the last 3 months. The average price target is $37.50, with a high forecast of $40.00 and a low forecast of $35.00. The average price target represents a 404.03% upside from the last price of $7.44.
Current Consensus is
The current consensus among 2 contributing investment analysts is to buy stock in Conversion Labs.
Conversion Labs, Inc. operates as a direct response healthcare company that provides over the counter products and prescription medications to consumers worldwide. The company's products include Shapiro MD, a shampoo, conditioner, and leave-in-foamer for treating hair loss; iNR Wellness MD, a nutritional supplement for immune and gut support; RexMD for the treatment of cold sores, mental health, and various other medical conditions faced by men; SOSRx, a telemedicine brand that offers prescription medications and over-the-counter emergency preparation supplies for disaster situations, such as flu epidemics, bacterial outbreaks, bioterrorism and water supply failures, and others; and PDFSimpli, a PDF conversion software enables users to convert, edit, and sign PDF documents. It markets and sells its products through advertisements on Facebook, Google, Amazon, and other social media and e-commerce platforms. The company was formerly known as Immudyne, Inc. and changed its name to Conversion Labs, Inc. in June 2018. Conversion Labs, Inc. was founded in 1994 and is based in New York, New York.